Latanoprost/netarsudil mesylate

Drug Profile

Latanoprost/netarsudil mesylate

Alternative Names: Latanoprost/AR-13324; Netarsudil/latanoprost ophthalmic solution - Aerie Pharmaceuticals; PG324; Roclatan

Latest Information Update: 03 Mar 2017

Price : $50

At a glance

  • Originator Aerie Pharmaceuticals
  • Class Antiglaucomas; Prostaglandins
  • Mechanism of Action Norepinephrine plasma membrane transport protein inhibitors; Prostaglandin F2 alpha agonists; Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Glaucoma; Ocular hypertension

Most Recent Events

  • 01 Mar 2017 Aerie Pharmaceuticals announces intention to submit NDA to US FDA in late 2017 or early 2018
  • 07 Dec 2016 Aerie Pharmaceuticals completes enrolment in its phase III Mercury-2 trial for Glaucoma and Ocular hypertension in USA
  • 14 Sep 2016 Efficacy data from the phase III MERCURY 1 trial in Ocular hypertension released by Aerie Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top